Skip to main content

Beneficial ownership — 13D / 13G

87,281 recent Schedule 13D / 13G filings — activist (13D) and passive (13G) stakes above 5% of a class.

Reporting person Issuer Schedule % of class Filed
VIKING GLOBAL INVESTORS LP VKTX Viking Therapeutics, Inc. 13G/A 5.1% 2y
T. Rowe Price Investment Management, Inc. EPAC Enerpac Tool Group Corp 13G/A 6.2% 2y
FIR TREE CAPITAL MANAGEMENT LP SHAP Spree Acquisition Corp. 1 Limited 13G 7.12% 2y
Walleye Capital LLC QOMO Qomolangma Acquisition Corp. Common Stock 13G 8.39% 2y
Crestview Partners III GP, L.P. PLGO Pelagos Insurance Capital Ltd 13G 14.4% 2y
Advent International, L.P. DH Definitive Healthcare Corp. 13G/A 53.7% 2y
JANUS HENDERSON GROUP PLC LXEO Lexeo Therapeutics, Inc. 13G 8.7% 2y
Deep Track Capital, LP GERN Geron Corp 13G/A 5.45% 2y
HGC Investment Management Inc. KVACF Keen Vision Acquisition Corp. 13G 6.2% 2y
OAKTOP CAPITAL MANAGEMENT II, L.P. PRTS CarParts.com, Inc. 13G/A 6.48% 2y
WCAS XIII Carbon Analytics Acquisition, L.P. CWAN Clearwater Analytics Holdings, Inc. 13G/A 26.9% 2y
J. Kyle Derham NPWR Net Power Inc. 13G/A 6.1% 2y
Nokomis Capital, L.L.C. CNTY Century Casinos Inc 13G 5.9% 2y
Divesh Makan GTLB Gitlab Inc. 13G/A 9.5% 2y
COHEN & STEERS, INC. WPC W. P. Carey Inc. 13G 5.21% 2y
3G Global Food Holdings LP KHC Kraft Heinz Co 13G/A 0% 2y
BAKER BROS. ADVISORS LP SGMT Sagimet Biosciences Inc. 13G 6.8% 2y
Fourthstone LLC AVBH Avidbank Holdings, Inc. 13G/A 9.89% 2y
First Trust Capital Management L.P. PGSS Pegasus Digital Mobility Acquisition Corp. 13G 8.78% 2y
Palo Alto Investors LP KPTI Karyopharm Therapeutics Inc. 13G/A 4.45% 2y
Alpha Wave Global, LP MVLA Movella Holdings Inc. Common Stock 13G 0% 2y
PRICE T ROWE ASSOCIATES INC /MD/ ARVN Arvinas, Inc. 13G 5.6% 2y
VIKING GLOBAL INVESTORS LP DNA Ginkgo Bioworks Holdings, Inc. 13G/A 8.8% 2y
PERCEPTIVE ADVISORS LLC MGTX MeiraGTx Holdings plc 13D/A 18% 2y
Calvin Choi HKD AMTD Digital Inc. 13G/A 14.2% 2y
Amundi PLNT Planet Fitness, Inc. 13G 5.5% 2y
Alger Associates, Inc. 13-3017981 CYRX Cryoport, Inc. 13G/A 4.1% 2y
PERCEPTIVE ADVISORS LLC VERU Veru Inc. 13G/A 3.8% 2y
Westchester Capital Management, LLC TLGYF Tlgy Acquisition Corp 13G 7.09% 2y
G. Leonard Baker, Jr. CORT Corcept Therapeutics Inc 13G/A 5.3% 2y
T. Rowe Price Investment Management, Inc. VRTS Virtus Investment Partners, Inc. 13G 5.6% 2y
John P. Szabo, Jr. INVE INVE Technologies, Inc. 13G/A 8.6% 2y
CITADEL ADVISORS LLC KVSA Khosla Ventures Acquisition Co. Class A Common Stock 13G/A 0% 2y
Nut Tree Capital Management, LP AVAH Aveanna Healthcare Holdings, Inc. 13G 6.5% 2y
Leonardo dos Santos Poça D’Água STIX Semantix, Inc. Class A Ordinary Shares 13G/A 33.1% 2y
P SCHOENFELD ASSET MANAGEMENT LP XAGE Longevity Health Holdings, Inc. 13G/A 0.5% 2y
CANADA PENSION PLAN INVESTMENT BOARD WOOF Petco Health & Wellness Company, Inc. 13G/A 30.6% 2y
Theodore J. Leonsis SG Sweetgreen, Inc. 13G/A 0.2% 2y
8 KNOTS MANAGEMENT, LLC EHTH eHealth, Inc. 13G/A 8.45% 2y
PRICE T ROWE ASSOCIATES INC /MD/ TW Tradeweb Markets Inc. 13G 7% 2y
ARMISTICE CAPITAL, LLC FREE Whole Earth Brands, Inc. Class A Common Stock 13G/A 5.02% 2y
PRICE T ROWE ASSOCIATES INC /MD/ KVUE Kenvue Inc. 13G 5.7% 2y
GLAZER CAPITAL, LLC ASCBF ASPAC II Acquisition Corp. 13G/A 2.18% 2y
BIOTECHNOLOGY VALUE FUND L P FDMT 4D Molecular Therapeutics, Inc. 13G/A 9.4% 2y
Deep Track Capital, LP NRIX Nurix Therapeutics, Inc. 13G/A 6.18% 2y
D. E. Shaw & Co., L.P. IRRX Integrated Rail and Resources Acquisition Corp. 13G/A 0% 2y
Antara Capital LP RVNC Revance Therapeutics, Inc. 13G/A 0% 2y
Clal Insurance Enterprises Holdings Ltd ELLO Ellomay Capital Ltd. 13G/A 12.2% 2y
COHEN & STEERS, INC. IRM Iron Mountain Inc 13G 7.85% 2y
Anson Funds Management LP SPRO Spero Therapeutics, Inc. 13G 8.1% 2y